Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Size, Share, By Therapy Type (Autologous TIL Therapy, Allogeneic TIL Therapy), By Indication (Indication, Hematologic Malignancies), By Source of TILs (Surgical Tumor Samples, Blood Samples), and By Region - Trends, Analysis and Forecast till 2034

Report Code: PMI556724 | Publish Date: August 2024 | No. of Pages: 186

Tumour Infiltrating Lymphocyte Therapy Market Companies

  • Iovance Biotherapeutics, Inc.
  • Adaptimmune Therapeutics plc
  • TCR2 Therapeutics Inc.
  • Lion Biotechnologies, Inc.
  • Kite Pharma, Inc.
  • Bristol-Myers Squibb Company
  • Novartis International AG
  • Celgene Corporation
  • Juno Therapeutics, Inc.
  • Allogene Therapeutics, Inc.
  • Syndax Pharmaceuticals, Inc.Forty Seven Inc.
  • Zymeworks Inc.
  • Arcellx, Inc.
  • Immatics Biotechnologies GmbH

Recent News:

  • The FDA approved TIL therapy for melanoma in July 2024. The US Food and Drug Administration has approved a novel TIL therapy for the treatment of metastatic melanoma. This marks an advance in the treatment of TIL therapy for Indication, paving the path for new treatment options for patients with metastatic melanoma.
  • In June 2024, a breakthrough in TIL expansion methods—Researchers from one of the world's largest oncology research centers have unveiled a groundbreaking upgrade to TIL expansion that enhances TIL growth and function. This research is anticipated to improve the efficiency and accessibility of TIL therapy to a more significant number of patients with cancer.
  • In April 2024, two top biotechnology companies announced an agreement to collaborate on the quest for evidence for TIL therapy. Their collaboration will focus on creating the next generation of TIL medicines and treatment combinations with other types of immunotherapies.